What is claimed is:

1. An isolated polypeptide comprising at least one VHH domain that binds PDL1 and at least one VHH domain that binds OX40, wherein at least one VHH domain that binds PDL1 comprises a complementarity determining region 1 (CDR1), a complementarity determining region 2 (CDR2), and a complementarity determining region 3 (CDR3) comprising an amino acid sequence selected from: SEQ ID NOs: 58, 59, and 60; SEQ ID NOs: 61, 62, and 63; SEQ ID NOs: 64, 65, and 66; SEQ ID NOs: 58, 65, and 67; SEQ ID NOs 58, 65, and 68; and SEQ ID NOs: 58, 69, and 70.

2. The isolated polypeptide of claim 1, wherein at least one VHH domain that binds PDL1 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 61; a CDR2 comprising the amino acid sequence of SEQ ID NO: 62; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 63.

3. The isolated polypeptide of claim 1 or claim 2, wherein at least one VHH domain that binds PDL1 is humanized.

4. The isolated polypeptide of any one of claims 1-3, wherein at least one VHH domain that binds PDL1 comprises an amino acid sequence that is at least 95% identical to an amino acid sequence selected from SEQ ID NOs: 52-57.

5. The isolated polypeptide of any one of claims 1-4, wherein at least one VHH domain that binds PDL1 comprises an amino acid sequence selected from SEQ ID NOs: 52-57.

6. The isolated polypeptide of any one of claims 1-5, wherein at least one VHH domain that binds PDL1 comprises the amino acid sequence of SEQ ID NO: 57.

7. The isolated polypeptide of any one of claims 1-6, wherein the polypeptide comprises one VHH domain that binds PDL1.

8. The isolated polypeptide of any one of claims 1-6, wherein the polypeptide comprises two VHH domains that bind PDL1.

9. The isolated polypeptide of any one of claims 1-8, wherein at least one VHH domain that binds OX40 comprises CDR1, CDR2, and CDR3 selected from: SEQ ID NOs: 30, 31, and 32; SEQ ID NOs: 30, 31, and 33; SEQ ID NOs: 30, 31, and 34; SEQ ID NOs: 30, 35, and 32; SEQ ID NOs: 36, 37, and 38; SEQ ID NOs: 36, 37, and 39; SEQ ID NOs: 36, 37, and 40; SEQ ID NOs: 36, 37, and 42; SEQ ID NOs: 36, 37, and 43; SEQ ID NOs: 44, 37, and 39; and SEQ ID NOs: 36, 37, and 45.

10. The isolated polypeptide of any one of claims 1-9, wherein at least one VHH domain that binds OX40 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 36, a CDR2 comprising the amino acid sequence of SEQ ID NO: 37, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 42; or comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 36, a CDR2 comprising the amino acid sequence of SEQ ID NO: 37, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 39.

11. The isolated polypeptide of any one of claim 1-10, wherein at least one VHH domain that binds OX40 is humanized.

12. The isolated polypeptide of claim 9 or claim 10, wherein at least one VHH domain that binds OX40 comprises an amino acid sequence that is at least 95% identical to an amino acid sequence selected from SEQ ID NOs: 377-385 and 29.

13. The isolated polypeptide of any one of claims 1-12, wherein at least one VHH domain that binds OX40 comprises an amino acid sequence selected from SEQ ID NOs: 377-385 and 29.

14. The isolated polypeptide of any one of claims 1-13, wherein the polypeptide comprises one VHH domain that binds OX40.

15. The isolated polypeptide of any one of claims 1-13, wherein the polypeptide comprises two VHH domains that bind OX40.

16. The isolated polypeptide of any one of claims 1-15, wherein the isolated polypeptide comprises an Fc region.

17. The isolated polypeptide of claim 16, wherein the Fc region comprises an amino acid sequence that is at least 97% identical to an amino acid sequence selected from SEQ ID NOs: 1-6.

18. The isolated polypeptide of claim 16, wherein the Fc region comprises an amino acid sequence selected from SEQ ID NOs: 1-6.

19. The isolated polypeptide of any one of claims 16-18, which forms a homodimer under physiological conditions.

20. The isolated polypeptide of any one of claims 16-19, wherein the polypeptide has the structure VHH-Linker-VHH-Linker-Hinge-Fc.

21. The isolated polypeptide of claim 20, wherein at least one linker is, independently, 5-20 amino acids in length.

22. The isolated polypeptide of claim 20 or claim 21, wherein the hinge comprises a sequence selected from SEQ ID NOs: 7-9.

23. The isolated polypeptide of any one of claims 16-22, which forms a dimer at physiological conditions.

24. An isolated polynucleotide that encodes the polypeptide of any one of claims 1-23.

25. An isolated cell that comprises the polynucleotide of claim 24.

26. An isolated cell that expresses the polypeptide of any one of claims 1-23.

27. A method of producing the polypeptide of any one of claims 1-23 comprising culturing the host cell of claim 25 or claim 26 under conditions suitable for producing the polypeptide.

28. Use of a polypeptide of any one of claims 1-23 in the manufacture of a medicament for treating cancer.

29. The use of claim 28, wherein the cancer is carcinoma, sarcoma, lymphoma, or leukemia.

30. An in vitro method of increasing T cell activation and/or proliferation comprising contacting T cells with a polypeptide of any one of claims 1-23.

31. The use of claim 28, wherein the polypeptide increases T cell activation and/or proliferation.